文摘
摘要目的:比较的诊断准确性τ([18F] Flortaucipir (FTP))和淀粉样宠物视觉读取区分阿尔茨海默病(AD)痴呆和amyloid-positive轻度认知障碍(MCI)从其他神经退行性疾病和认知正常(CN)控制。
背景:的诊断性能FTP-PET最近获得FDA批准,没有比淀粉样宠物临床相关的队列中。
设计/方法:加州大学旧金山分校的661名参与者进行了FTP和淀粉样宠物,隆德大学,或者Gangnam遣散医院。淀粉样宠物追踪器是特定站点(加州大学旧金山分校,11C]加以;隆德,(18F] Flutemetamol;Gangnam, (18F] Florbetaben)。三个视觉评级机构解释淀粉样宠物使用tracer-specific标准和FTP-PET使用方法由派系et al。(2021)。一个视觉评定等级也解释FTP-PET扫描使用fda批准的目视判读方法。淀粉样蛋白和FTP-PET阅读每个读者在不同,随机批次。绝大多数的解释每个扫描淀粉样积极/消极和τ积极/消极是用于主要分析。诊断性能的FTP和淀粉样宠物视觉读取和kappa统计为内部和两分的计算可靠性。FTP-PET视觉阅读方法比较使用kappa统计和McNemar检验法测试。
结果:淀粉样蛋白和FTP-PET视觉读取有相似的敏感性(92.6%,95%置信区间(88.7 - -95.9%),92.2%(-95.2% - 88.2),分别)和特异性(82.9%(78.9 - -86.5%),78.2%(-82.1% - 73.9),分别)区分广告和amyloid-positive MCI其它痴呆和CN控制。FTP-PET intra-rater可靠性是κ= 0.80 - -1.00 (p < 0.0001),和两分的读者之间对可靠性范围从κ= 0.78 - -0.85 (p < 0.0001)。淀粉样宠物intra-rater可靠性是κ= 0.97 (p < 0.0001)为每个读者,和两分的读者之间对可靠性范围从κ= 0.82 - -0.88 (p < 0.0001)。之间有温和的协议FTP-PET视觉阅读方法(κ= 0.58),但是他们统计不同(χ2= 17,p < 0.0001)差异的解释示踪剂保留在中央的和前外侧颞叶皮层。
结论:FTP和淀粉样宠物视觉读取诊断性能和高内部有相似和两分的可靠性。
披露:Soleimani-Meigooni博士没有披露。史密斯博士的直系亲属成员已收到个人赔偿的鳄鱼生物科学作为一个员工。史密斯博士的机构已经接到欧盟——JPND研究支持。史密斯博士的机构已经接到Alzheimerfonden研究支持。史密斯博士的直系亲属成员已收到知识产权利益从发现或技术相关的卫生保健。教务长博士已经收到个人薪酬在500 - 4999美元的范围作为顾问Optina诊断公司. .教务长博士已经收到个人补偿的范围为0 - 499美元作为顾问Biospective Inc . .劳伦·爱德华兹没有披露。莱昂纳多Iaccarinohas nothing to disclose. The institution of Renaud La Joie has received research support from NIH. The institution of Renaud La Joie has received research support from Alzheimer's Association. Mr. Strandberg has nothing to disclose.Amelia Strom has nothing to disclose. Dr. Lyoo has nothing to disclose.Prof. Hansson has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen. Prof. Hansson has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche. Dr. Rabinovici has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Eisai. Dr. Rabinovici has received personal compensation in the range of $500-$4,999 for serving as a Consultant for GE Healthcare. Dr. Rabinovici has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche. Dr. Rabinovici has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Genentech. Dr. Rabinovici has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eli Lilly. Dr. Rabinovici has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Johnson & Joihnson. Dr. Rabinovici has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for JAMA Neurology. The institution of Dr. Rabinovici has received research support from NIH. The institution of Dr. Rabinovici has received research support from American College of Radiology. The institution of Dr. Rabinovici has received research support from Alzheimer's Association. The institution of Dr. Rabinovici has received research support from Rainwater Charitable Foundation. The institution of Dr. Rabinovici has received research support from Genentech. Dr. Rabinovici has received personal compensation in the range of $5,000-$9,999 for serving as a Topic Chair, Course Director and teacher with AAN. Dr. Rabinovici has received personal compensation in the range of $500-$4,999 for serving as a Grant reviewer with NIH.
